Details of the Drug

General Information of Drug (ID: DM12UX6)

Drug Name
131 I-omburtamab
Indication
Disease Entry ICD 11 Status REF
Brain and central nervous system tumour 2A00.11 Phase 2/3 [1]
Neuroblastoma 2D11.2 Phase 2/3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DKJ93L
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B7 homolog 3 (CD276) TT6CQUM CD276_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain and central nervous system tumour
ICD Disease Classification 2A00.11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B7 homolog 3 (CD276) DTT CD276 3.92E-01 -0.04 -0.81
B7 homolog 3 (CD276) DTT CD276 7.33E-02 -0.53 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03275402) 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. U.S. National Institutes of Health.
2 IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.